Immunotherapy: A Complete Patient and Family Guide

At a glance: Immunotherapy is cancer treatment that helps the immune system recognize, target, control, or destroy cancer. It may release immune-system “brakes,” mark cancer cells for attack, redirect immune cells toward a tumor, provide cancer-recognition instructions, or strengthen particular immune responses.

Important: Immunotherapy is not one drug, one procedure, or one predictable experience. It includes several distinct treatment classes. Eligibility, expected benefits, testing requirements, treatment schedules, and side effects depend on the exact therapy and the individual patient.

Essential safety message: Some immunotherapies can cause the immune system to inflame healthy organs. A mild-looking symptom—such as diarrhea, rash, cough, unusual fatigue, headache, or weakness—can occasionally be the beginning of a serious immune-related reaction.

Report new or worsening symptoms promptly, including symptoms that appear after immunotherapy has stopped. Do not wait for the next appointment when the oncology team has told you to call.

Personalized-care reminder: Never start, stop, delay, or restart immunotherapy or medicines used to control its side effects without instructions from the oncology team. Corticosteroids and other immune-suppressing medicines may be medically necessary and should not be adjusted independently.

Quick Jump: Immunotherapy Topics

• What Is Immunotherapy?
• The Immune System and Cancer
• Goals of Immunotherapy
• Who May Benefit?
• When Immunotherapy May Not Be Recommended
• Types of Immunotherapy
• Immune Checkpoint Inhibitors
• Monoclonal and Bispecific Antibodies
• T-Cell and Cellular Therapies
• CAR T-Cell Therapy
• TIL and TCR Therapy
• Cancer Treatment Vaccines
• Oncolytic Virus Therapy
• Immune-System Modulators
• Biomarkers and Eligibility Testing
• How a Treatment Plan Is Selected
• How Immunotherapy Is Given
• Schedules and Treatment Duration
• Preparing for Immunotherapy
• What Happens on Treatment Day?
• Monitoring During Treatment
• How Doctors Know It Is Working
• Common Side Effects
• Immune-Related Organ Inflammation
• Infusion and Allergic Reactions
• Cytokine Release Syndrome
• Neurologic Toxicity and ICANS
• Urgent Warning Signs
• How Side Effects Are Managed
• Autoimmune Disease and Transplants
• Infections and Vaccinations
• Pregnancy, Fertility and Sexual Health
• Combination Treatment
• Long-Term Monitoring
• Nutrition and Physical Activity
• Supportive and Integrative Care
• Work, Travel and Daily Life
• Questions to Ask the Care Team
• Immunotherapy Myths and Facts
• Clinical Trials and New Directions
• Costs and Financial Planning
• Treatment Checklist
• Trusted Resources

Immunotherapy is a type of biological cancer treatment that uses or modifies parts of the immune system to fight cancer. Some treatments use laboratory-made substances. Others collect, expand, or genetically modify a patient’s own immune cells before returning them to the body.

Immunotherapy may work by:

• Removing signals that turn immune cells off
• Helping immune cells recognize cancer-associated targets
• Marking cancer cells for immune destruction
• Bringing immune cells into close contact with cancer cells
• Expanding cancer-fighting immune cells in a laboratory
• Giving immune cells new receptors that recognize cancer
• Training the immune system to respond to tumor antigens
• Stimulating immune activity within a tumor or body cavity

Most drug-based immunotherapies are systemic because they circulate through the bloodstream. Others are delivered directly into a tumor, the bladder, or another treatment site. Cellular immunotherapies may require a specialized collection, manufacturing, conditioning, infusion, and monitoring process.

National Cancer Institute: Immunotherapy to Treat Cancer

Important distinction: Immunotherapy is not the same as generally “boosting the immune system.” The immune system is highly regulated. Effective immunotherapy targets particular biological pathways, cells, receptors, or tumor antigens. Vitamins, herbs, detox products, and immune-boosting supplements do not reproduce these treatments.

The immune system routinely identifies infections, damaged cells, and some abnormal cells. Immune cells can sometimes enter tumors and attempt to destroy cancer. These cells may be described as tumor-infiltrating lymphocytes.

Cancer develops from the body’s own cells, which makes recognition difficult. Cancer cells may avoid immune destruction by:

• Becoming less visible to immune cells
• Reducing or losing recognizable antigens
• Producing proteins that switch T cells off
• Creating an immune-suppressing environment around the tumor
• Recruiting cells that weaken immune responses
• Changing after treatment so the original immune target is no longer present
• Preventing immune cells from entering or functioning within the tumor

Immunotherapy attempts to overcome one or more of these defenses. However, a treatment that works for one tumor may not work for another because cancers differ in their mutations, proteins, immune environment, location, and resistance mechanisms.

Not every patient responds to immunotherapy. Some people experience deep and long-lasting responses, while others have temporary benefit or no measurable response.

1. Curative Treatment

For selected cancers and patients, immunotherapy may help produce a complete and lasting remission. The possibility of cure depends on the exact cancer, stage, treatment type, biomarkers, and response.

2. Neoadjuvant Immunotherapy

Immunotherapy may be given before surgery to reduce cancer, treat microscopic disease early, improve surgical outcomes, or provide information about treatment response.

3. Adjuvant Immunotherapy

Immunotherapy may be given after surgery to reduce the risk that cancer will return by treating remaining microscopic cancer cells.

4. Treatment of Advanced or Metastatic Cancer

Immunotherapy may shrink cancer, slow growth, control symptoms, extend survival, or produce a long-term remission in selected advanced cancers.

5. Treatment of Recurrent Cancer

A cancer that returns after surgery, chemotherapy, radiation, or another treatment may respond to immunotherapy, particularly when relevant biomarkers or immune targets are present.

6. Maintenance Treatment

Immunotherapy may continue after an initial response to help maintain cancer control for a planned period or until the treatment should be stopped.

7. Organ-Preserving Treatment

In selected research-supported settings, an immunotherapy response may reduce the extent of local treatment needed. Such decisions require careful multidisciplinary evaluation and should not be generalized to every cancer.

8. Symptom and Disease Control

Even when cure is not expected, immunotherapy may control cancer and preserve quality of life. Palliative-care services can be provided at the same time to manage symptoms and support patients and families.

Immunotherapy may be considered when one or more of the following apply:

• The cancer type and stage have an evidence-supported immunotherapy option.
• The tumor has a biomarker associated with possible benefit.
• The cancer expresses a target recognized by a monoclonal antibody or cell therapy.
• The cancer has returned or progressed after other treatment.
• Immunotherapy can reduce recurrence risk after surgery.
• Immunotherapy is recommended before surgery.
• The treatment can be combined safely with chemotherapy, radiation, targeted therapy, or another immunotherapy.
• A specialized cellular therapy is available for the cancer and patient.
• A clinical trial offers a scientifically appropriate immunotherapy option.

Immunotherapy may not be the preferred treatment when:

• The cancer is unlikely to respond to the available immunotherapy.
• A required target or eligibility biomarker is absent.
• Surgery, chemotherapy, radiation, hormone therapy, targeted therapy, or surveillance is expected to provide greater benefit.
• A serious uncontrolled autoimmune condition creates excessive risk.
• An organ transplant could be endangered by immune activation.
• A serious infection or unstable medical problem must be treated first.
• The patient requires immune-suppressing treatment that may conflict with the proposed therapy.
• Previous immunotherapy caused a severe or life-threatening reaction.
• Heart, lung, liver, kidney, nervous-system, or other organ problems make the treatment excessively risky.
• The expected benefit is small compared with treatment burden or potential harm.
• The patient decides that the treatment does not match their priorities or goals.

These issues are not always absolute exclusions. Some patients with autoimmune disease, infection history, organ dysfunction, or previous immune toxicity may still receive carefully selected treatment after specialist evaluation.

• Immune checkpoint inhibitors: Block signals that restrain cancer-fighting T cells.
• Monoclonal antibodies: Bind to specific targets and may mark cancer cells or recruit immune destruction.
• Bispecific antibodies: Bind two targets and may bring an immune cell directly to a cancer cell.
• CAR T-cell therapy: Genetically modifies a patient’s T cells to recognize a cancer target.
• Tumor-infiltrating lymphocyte therapy: Collects T cells from a tumor, expands them, and returns them to the patient.
• T-cell receptor therapy: Adds a selected cancer-recognizing T-cell receptor to a patient’s T cells.
• Cancer treatment vaccines: Train or strengthen immune responses against tumor antigens.
• Oncolytic virus therapy: Uses a modified virus to infect cancer cells and stimulate antitumor immunity.
• Immune-system modulators: Strengthen or alter immune activity through cytokines, BCG, or other agents.

Classification can overlap: Some monoclonal and bispecific antibodies are described as immunotherapy, targeted therapy, or both. Ask the oncology team to explain how each medicine works rather than relying only on the category name.

Immune checkpoints are normal safety systems that prevent immune responses from becoming excessively strong and damaging healthy tissue. Cancer cells may exploit these checkpoints to turn T cells off.

Checkpoint inhibitors block an immune checkpoint or its partner protein, preventing an “off” signal and allowing T cells to respond more strongly to cancer.

Important checkpoint pathways include:

• PD-1: A checkpoint protein found on T cells
• PD-L1: A partner protein that may be present on cancer or other cells
• CTLA-4: A checkpoint involved in regulating T-cell activation
• LAG-3: Another immune-regulating pathway targeted in selected treatment combinations

Checkpoint inhibitors are used for selected patients with melanoma, lung cancer, kidney cancer, bladder cancer, breast cancer, colorectal cancer, head and neck cancer, liver cancer, lymphoma, stomach and esophageal cancers, cervical and endometrial cancers, and other malignancies.

Some checkpoint inhibitors are approved according to a molecular feature rather than the tumor’s original organ. This is sometimes called tumor-agnostic or tissue-agnostic treatment.

National Cancer Institute: Immune Checkpoint Inhibitors

Antibodies are immune-system proteins that recognize particular targets. Monoclonal antibodies used in cancer treatment are manufactured to bind a selected molecule.

An antibody may:

• Mark a cancer cell so immune cells can recognize and destroy it
• Block a growth signal used by the cancer
• Activate immune cells through antibody-dependent mechanisms
• Carry a drug, toxin, or radioactive material to a cancer target
• Bring two different cells or proteins together
• Block an immune checkpoint

Bispecific Antibodies

A bispecific antibody binds two different targets. Some are designed to attach to a cancer cell with one arm and a T cell with the other, bringing them together so the T cell can attack.

Bispecific immune-cell engagers can cause infusion reactions, cytokine release syndrome, infection, neurologic symptoms, and blood-count changes. Monitoring depends on the specific product and treatment schedule.

National Cancer Institute: Monoclonal Antibodies

Cellular immunotherapy uses living immune cells as treatment. Cells may be collected from the patient’s blood or tumor, selected or genetically modified in a laboratory, expanded into large numbers, and infused back into the patient.

Major forms include:

• CAR T-cell therapy
• Tumor-infiltrating lymphocyte therapy
• T-cell receptor therapy
• Other investigational T-cell, natural-killer-cell, and engineered-cell approaches

Cellular therapy is usually more complex than a routine infusion. It can involve cell collection, manufacturing, temporary cancer-control treatment, lymphodepleting chemotherapy, hospitalization or close outpatient monitoring, infection precautions, and long-term follow-up.

National Cancer Institute: T-Cell Transfer Therapy

CAR T-cell therapy uses T cells that have been genetically modified to produce a chimeric antigen receptor, or CAR. The receptor helps the T cells recognize a selected protein on cancer cells.

Typical CAR T-Cell Treatment Process

1. Evaluation: The center confirms the diagnosis, target, previous treatment, organ function, infection status, and medical eligibility.
2. Leukapheresis: Blood passes through a machine that removes selected white blood cells and returns the remaining blood.
3. Manufacturing: The patient’s T cells are genetically modified and expanded in a laboratory.
4. Bridging treatment: Some patients receive temporary treatment to control cancer while the cells are being manufactured.
5. Lymphodepleting chemotherapy: Short-course chemotherapy may be given to prepare the body for the modified cells.
6. Cell infusion: The CAR T cells are infused through a vein.
7. Close monitoring: The patient is watched for cytokine release syndrome, neurologic effects, infection, low blood counts, and other complications.
8. Long-term follow-up: Ongoing monitoring is required for treatment response, immune recovery, infection risk, and delayed complications.

CAR T-cell therapies are established for selected leukemias, lymphomas, and multiple myeloma. Research is continuing in solid tumors and additional blood cancers.

Patients commonly need to remain near the treating center for a defined period and may temporarily be advised not to drive. Follow the product-specific instructions supplied by the cellular-therapy center.

National Cancer Institute: CAR T Cells—Engineering Immune Cells to Treat Cancer

CAR T-cell long-term safety: FDA labeling for BCMA- and CD19-directed genetically modified autologous CAR T-cell therapies includes warnings about secondary T-cell malignancies. Patients receiving these products should receive lifelong monitoring for secondary cancers.

FDA: Boxed Warning for T-Cell Malignancies After Selected CAR T-Cell Therapies

Tumor-Infiltrating Lymphocyte Therapy

TIL therapy begins with immune cells collected from surgically removed tumor tissue. The cells that recognize the tumor are selected or expanded into large numbers and infused back into the patient.

Treatment may require tumor-removal surgery, cell manufacturing, lymphodepleting chemotherapy, the TIL infusion, immune-stimulating medicine, and intensive supportive care. TIL therapy is available for selected patients with advanced melanoma and is being studied in other solid tumors.

T-Cell Receptor Therapy

TCR therapy genetically modifies a patient’s T cells so they produce a receptor that recognizes a specific cancer-associated antigen. Unlike CARs, T-cell receptors recognize antigen fragments presented through HLA proteins.

Eligibility can require testing for both the tumor antigen and a compatible HLA type. TCR therapy is available for selected patients with particular cancers and remains an active area of research.

Cell-therapy eligibility is highly specific. The presence of the correct target, HLA type, treatment history, tumor access, organ function, and ability to tolerate conditioning treatment may all matter.

Cancer treatment vaccines are designed for people who already have cancer. They help the immune system recognize tumor-associated antigens and respond against cancer cells that contain those antigens.

Treatment vaccines may be created from:

• A patient’s tumor cells
• A patient’s dendritic cells
• Proteins or antigens found on cancer cells
• Genetic instructions encoding cancer-associated antigens
• Personalized neoantigens identified from a patient’s tumor

A dendritic-cell treatment vaccine is used for selected patients with advanced prostate cancer. Many additional cancer vaccines remain investigational.

National Cancer Institute: Cancer Treatment Vaccines

Oncolytic virus therapy uses a virus that has been selected or modified to infect and damage cancer cells while stimulating an immune response against the tumor.

Treatment may be injected directly into accessible tumors. Possible effects include flu-like symptoms, injection-site discomfort, fatigue, and local inflammation. Patients may receive instructions about dressings, contact with treatment material, pregnancy, and people with weakened immune systems.

Oncolytic virus therapy is used in selected cancers and continues to be studied in combination with checkpoint inhibitors, radiation, and other treatments.

Immune-system modulators strengthen, direct, or alter immune activity. They include cytokines, BCG, and selected immunomodulating medicines.

Cytokines

Cytokines are signaling proteins used by immune cells. Interferons and interleukins can stimulate immune responses and may be used for selected cancers. They can cause fever, chills, weakness, blood-pressure changes, fluid shifts, and other significant effects.

BCG Therapy

Bacillus Calmette-Guérin, or BCG, is placed directly into the bladder through a catheter for selected non-muscle-invasive bladder cancers. It produces a local immune response against bladder cancer cells.

Patients receive instructions about retaining the treatment, bathroom hygiene, household cleaning, and symptoms that require urgent contact. Fever, chills, severe urinary symptoms, or signs of systemic illness require prompt medical guidance.

Immunomodulatory Medicines

Selected medicines alter immune-cell behavior and the tumor environment and are used in certain blood cancers and other conditions. They may also have anti-angiogenic or direct anticancer activity.

National Cancer Institute: Immune-System Modulators

Biomarker testing examines genes, proteins, immune targets, or other features that may help predict whether a treatment is appropriate. Testing may use tumor tissue, blood, bone marrow, or another specimen.

Immunotherapy-related biomarkers may include:

• PD-L1 expression: Measures the amount or distribution of PD-L1 in tumor or immune cells
• Mismatch repair deficiency: Indicates impaired repair of DNA-copying errors
• Microsatellite instability-high: Reflects instability caused by abnormal DNA mismatch repair
• Tumor mutational burden: Estimates the number of mutations within a tumor
• Cancer-cell surface targets: Such as proteins recognized by CAR T cells or antibodies
• Tumor antigens: Targets required for selected vaccines or T-cell receptor therapies
• HLA type: May determine eligibility for certain TCR therapies
• Immune-cell characteristics: Sometimes assessed in specialized care or clinical trials

Biomarkers are not perfect guarantees. A person with a favorable biomarker may not respond, and a person without a high biomarker level may sometimes benefit, depending on the cancer and approved treatment setting.

Testing methods and cutoff values can differ. Ask which laboratory performed the test, whether the sample was adequate, what result was obtained, and how it changes the treatment recommendation.

National Cancer Institute: Biomarker Testing for Cancer Treatment

The oncology team may consider:

• The exact cancer type, subtype, stage, and grade
• Tumor biomarkers and immune targets
• The treatment goal
• Previous surgery, chemotherapy, radiation, targeted therapy, and immunotherapy
• Past treatment response or resistance
• Autoimmune or inflammatory diseases
• Prior organ or stem-cell transplantation
• Current or recent infections
• Heart, lung, liver, kidney, endocrine, and nervous-system function
• Medicines that suppress or alter immune activity
• Pregnancy, fertility, and reproductive considerations
• Ability to attend frequent monitoring or remain near a specialized center
• Patient preferences, quality-of-life priorities, access, and cost

The treatment plan should identify the therapy’s full generic name, treatment goal, route, schedule, expected duration, monitoring tests, likely side effects, emergency instructions, and conditions that would lead to delaying or stopping treatment.

Intravenous Infusion

Many checkpoint inhibitors, antibodies, cytokines, and cellular therapies are given through a vein. Treatment may use a temporary IV, port, or central catheter.

Subcutaneous Injection

Selected immune therapies are injected under the skin.

Intramuscular Injection

Some immune-stimulating medicines or vaccine-based approaches may be injected into a muscle.

Intravesical Treatment

BCG or another treatment may be placed into the bladder through a catheter.

Intratumoral Treatment

An oncolytic virus, immune stimulant, or investigational treatment may be injected directly into a tumor.

Oral Treatment

Some immune-modulating medicines are available as pills or capsules. Oral treatment still requires accurate dosing, interaction review, laboratory monitoring, and safe handling.

Cell Infusion

CAR T, TIL, TCR, and other cellular products are infused through a vein after the required preparation and safety checks.

Immunotherapy schedules vary substantially. Treatment may be given:

• Every week
• Every two, three, four, or six weeks
• In several closely monitored doses
• As a one-time cellular infusion
• As repeated injections into a tumor
• As a time-limited adjuvant or neoadjuvant course
• Until a planned maximum duration
• Until cancer progresses or side effects become unacceptable

Treatment may be delayed, suspended, or stopped because of:

• Suspected immune-related inflammation
• Infusion or allergic reaction
• Infection
• Abnormal liver, kidney, thyroid, adrenal, pituitary, heart, or other testing
• Neurologic symptoms
• Need for high-dose immune-suppressing treatment
• Cancer progression
• Completion of the planned course
• A deep response that changes the risk-benefit balance

A treatment hold does not automatically mean immunotherapy has failed. Pausing treatment can be essential while a possible immune-related complication is evaluated and treated.

Understand the Treatment

• Write down the full generic name of the treatment.
• Ask which type of immunotherapy it is.
• Understand the treatment goal and expected benefit.
• Ask whether biomarker testing supports the recommendation.
• Learn the treatment schedule and planned duration.
• Know how the team will determine whether it is working.

Report Medical Conditions

Tell the oncology team about any history of:

• Autoimmune or inflammatory disease
• Organ transplantation
• Stem-cell transplantation
• Lung, heart, liver, kidney, endocrine, or neurologic disease
• Diabetes or thyroid disease
• Inflammatory bowel disease
• Rheumatologic disease
• Severe skin disease
• Previous immune-related treatment reaction
• Chronic infection or recent serious infection
• Pregnancy or breastfeeding

Review Every Medicine and Supplement

Provide a complete list of prescriptions, nonprescription medicines, vitamins, herbs, supplements, cannabis products, and other substances. Include corticosteroids and medicines prescribed by specialists. Do not stop a necessary medicine simply because it affects the immune system.

Baseline Testing

The team may perform:

• Complete blood count
• Liver and kidney testing
• Thyroid, adrenal, pituitary, and blood-sugar testing
• Pregnancy testing when relevant
• Infection screening
• Heart testing for selected patients
• Lung assessment
• Neurologic examination
• Baseline imaging
• Biomarker or immune-target testing

Create an Emergency Plan

• Save daytime and after-hours oncology numbers.
• Know which hospital should evaluate urgent problems.
• Ask whether you should carry an immunotherapy alert card.
• Tell family or caregivers which symptoms require immediate contact.
• Keep the drug name and last-treatment date available.

Symptom Review

The nurse or clinician may ask about bowel movements, breathing, skin, energy, appetite, headaches, vision, muscle strength, urination, pain, fever, and hormonal symptoms. Report all new changes, even when they appear unrelated to cancer.

Laboratory Review

Blood tests may be checked before treatment. Abnormal results can reveal liver, kidney, thyroid, adrenal, blood-count, or blood-sugar problems before obvious symptoms occur.

Access and Premedication

A vein or central-access device is used for infused treatment. Some therapies require antihistamines, fever-reducing medicines, corticosteroids, fluids, or other premedications.

Treatment and Observation

The medicine or cells are given at the prescribed rate. Monitoring may include temperature, blood pressure, heart rate, oxygen level, mental status, and symptoms. Observation time depends on the treatment and previous reactions.

Before Leaving

The patient should know which treatment was given, when home medicines should be taken, what symptoms to report, when the next laboratory tests are due, and whom to contact after hours.

Monitoring may include:

• Physical examinations
• Complete blood counts
• Liver and kidney tests
• Thyroid and adrenal testing
• Blood-sugar testing
• Heart tests when indicated
• Oxygen levels and lung imaging
• Neurologic assessments
• CT, MRI, PET, or other cancer-response imaging
• Infection and immune-recovery testing after cellular therapy

Side effects may occur:

• During an infusion
• Hours or days after treatment
• After several doses
• Months into treatment
• After immunotherapy has been delayed or stopped

Continue to tell every clinician that you received immunotherapy. New symptoms appearing after treatment may still require evaluation for immune-related inflammation.

Treatment response may be evaluated through:

• Physical examinations
• Changes in symptoms and function
• CT, MRI, PET, ultrasound, or other imaging
• Blood tests and tumor markers
• Bone-marrow testing for selected blood cancers
• Pathology after surgery
• Specialized testing for cellular therapies

Possible response categories include complete response, partial response, stable disease, and progressive disease.

Pseudoprogression

Occasionally, a tumor may appear larger on an early scan because immune cells and inflammation have entered the area, or a previously unseen lesion becomes visible before later improvement. This pattern is called pseudoprogression.

Pseudoprogression is not common enough to assume that every larger scan represents immune activity. The oncology team considers symptoms, scan patterns, tumor type, laboratory results, and follow-up imaging before deciding whether treatment should continue.

Side effects do not prove that immunotherapy is working. Severe immune toxicity does not guarantee a response, and having few side effects does not mean treatment has failed.

Potential effects vary according to the treatment class. Commonly reported symptoms can include:

• Fatigue
• Rash or itching
• Diarrhea
• Fever or chills
• Muscle or joint aches
• Headache
• Nausea or reduced appetite
• Cough or shortness of breath
• Injection-site or infusion-site reactions
• Blood-pressure changes
• Hormonal changes
• Blood-count changes
• Infection risk with selected cellular or combination treatments

Do not grade a symptom yourself: The seriousness of an immune-related effect cannot always be judged by appearance alone. Contact the oncology team so it can determine whether testing or immediate treatment is needed.

Checkpoint inhibitors and some other immunotherapies can cause immune cells to attack healthy organs. These complications are often called immune-related adverse events.

Skin

• Rash
• Itching
• Changes in skin color
• Blisters, peeling, sores, or painful skin

Colon and Digestive Tract

• New or increasing diarrhea
• Abdominal pain or cramping
• Mucus or blood in stool
• Black stool
• Nausea or vomiting

Liver

• Abnormal liver tests without obvious symptoms
• Yellow skin or eyes
• Dark urine
• Right-sided abdominal pain
• Nausea, unusual bruising, or severe fatigue

Lungs

• New or worsening cough
• Shortness of breath
• Chest discomfort
• Reduced oxygen level
• Inflammation called pneumonitis

Thyroid, Pituitary and Adrenal Glands

• Unusual fatigue or weakness
• Headache
• Dizziness or faintness
• Weight gain or loss
• Feeling unusually cold or hot
• Constipation or diarrhea
• Blood-pressure changes
• Mood or concentration changes

Pancreas and Blood Sugar

• Severe abdominal pain
• Vomiting
• Extreme thirst
• Frequent urination
• Unexpected weight loss
• New high blood sugar or diabetes

Kidneys

• Reduced urine
• Blood in urine
• Swelling
• Abnormal kidney tests
• Inflammation called nephritis

Heart

• Chest pain
• Shortness of breath
• Fast, irregular, or pounding heartbeat
• Faintness
• Swelling
• Heart-muscle inflammation called myocarditis

Nervous System and Muscles

• Numbness or tingling
• Muscle weakness
• Difficulty walking
• Facial weakness
• Difficulty swallowing or breathing
• Confusion, seizure, or severe headache
• Inflammation of nerves, muscles, brain, or spinal structures

Eyes

• Eye pain
• Redness
• Light sensitivity
• Blurred or reduced vision

Joints and Rheumatologic Effects

• Joint pain or swelling
• Muscle pain or weakness
• Stiffness
• New inflammatory or autoimmune symptoms

Tell the nurse immediately during an infusion if you develop:

• Itching, hives, flushing, or rash
• Fever, chills, or shaking
• Chest tightness
• Throat tightness or trouble swallowing
• Shortness of breath or wheezing
• Swelling of the face, lips, or tongue
• Dizziness or faintness
• Sudden back, chest, or abdominal pain
• Rapid heartbeat
• A sudden sense that something is seriously wrong

The infusion may be stopped while the team evaluates the reaction. Treatment can include oxygen, fluids, antihistamines, corticosteroids, fever-reducing medicines, or emergency medications.

Depending on severity, the infusion may restart more slowly, require additional premedication, be changed, or be permanently discontinued.

Cytokine release syndrome, or CRS, can occur when activated immune cells release large amounts of inflammatory signaling proteins. It is particularly associated with CAR T-cell therapy and some bispecific antibodies, although other immune therapies can also produce cytokine-related reactions.

Possible symptoms include:

• Fever
• Chills
• Severe fatigue
• Nausea or vomiting
• Headache
• Muscle aches
• Rapid heartbeat
• Low blood pressure
• Low oxygen level
• Trouble breathing
• Confusion or organ dysfunction in severe cases

CRS can range from mild to life-threatening. Treatment may include supportive care, oxygen, intravenous fluids, medicines that block inflammatory cytokines, corticosteroids, and intensive-care monitoring.

Follow the cellular-therapy center’s fever instructions exactly. Fever after cellular or bispecific therapy requires immediate assessment because it may represent CRS, infection, or both.

CAR T-cell therapy and some immune-cell-engaging treatments can cause neurologic toxicity. A syndrome associated with immune effector cells is called immune effector cell-associated neurotoxicity syndrome, or ICANS.

Possible warning signs include:

• New confusion
• Difficulty paying attention
• Unusual sleepiness or agitation
• Difficulty speaking or finding words
• Writing changes
• Tremor
• Weakness
• Loss of coordination
• Seizure
• Reduced consciousness

The care team may perform repeated orientation, handwriting, language, and neurologic assessments. Treatment depends on severity and may require corticosteroids, seizure medicines, intensive monitoring, or other interventions.

Patients should not drive or operate dangerous equipment during the restricted period specified by the treatment center.

Follow the emergency instructions provided by your treatment center. Contact the oncology team immediately for:

• Fever at or above the team’s reporting threshold
• New or worsening shortness of breath
• New cough, chest pain, or low oxygen level
• Severe diarrhea or a major increase in bowel movements
• Blood or mucus in stool
• Severe abdominal pain
• Yellow skin or eyes
• Dark urine or major decrease in urine
• Severe headache, confusion, seizure, fainting, or unusual sleepiness
• New weakness, numbness, difficulty walking, speaking, swallowing, or breathing
• Rapid, irregular, or pounding heartbeat
• Severe dizziness or low blood pressure
• Extreme thirst, frequent urination, or signs of very high blood sugar
• New severe rash, blistering, peeling, mouth sores, or painful skin
• Eye pain or sudden vision change
• Persistent vomiting or inability to keep liquids down
• Facial, tongue, or throat swelling
• Any new symptom after CAR T-cell, TIL, TCR, or bispecific-antibody treatment
• Any symptom specifically identified as urgent in the treatment instructions

Seek emergency medical care for severe breathing difficulty, loss of consciousness, seizure, signs of stroke, severe chest pain, uncontrolled bleeding, or another immediately life-threatening problem.

Management depends on the treatment, organ affected, symptom severity, test results, infection risk, and whether the cancer is responding.

The care team may:

• Continue treatment with closer monitoring
• Hold one or more doses
• Order blood tests, imaging, endoscopy, heart tests, or specialist evaluations
• Give topical treatment for mild skin symptoms
• Use corticosteroids to reduce immune inflammation
• Use another immune-suppressing medicine when corticosteroids are insufficient
• Replace hormones permanently or temporarily
• Treat infection at the same time
• Provide oxygen, fluids, or hospital monitoring
• Permanently stop the immunotherapy after selected severe reactions

Corticosteroid treatment may need to continue for days or weeks and then be reduced gradually. Stopping corticosteroids suddenly can be dangerous after prolonged or high-dose use.

Some endocrine complications cause permanent loss of hormone production. In these cases, the inflammation may settle, but long-term hormone-replacement medicine can still be necessary.

Never treat suspected immune-related diarrhea, cough, headache, weakness, or rash solely with nonprescription medicines without contacting the oncology team. Symptom suppression can delay recognition of serious inflammation.

Patients should tell the oncology team about every autoimmune or inflammatory condition, including conditions that have been quiet for years.

Examples include:

• Rheumatoid arthritis
• Lupus
• Psoriasis or psoriatic arthritis
• Inflammatory bowel disease
• Multiple sclerosis
• Myasthenia gravis
• Autoimmune thyroid disease
• Autoimmune hepatitis
• Vasculitis
• Other immune-mediated disorders

Checkpoint inhibitors may cause an autoimmune flare or a new immune-related complication. Some patients can still be treated after careful evaluation by oncology and the relevant specialist.

Immune activation can also threaten a transplanted organ. Patients with a kidney, liver, heart, lung, or other organ transplant require highly individualized risk assessment.

Do not hide autoimmune or transplant history because of fear that treatment will be denied. Accurate information allows the team to compare risks, alternatives, and monitoring strategies.

Checkpoint inhibitors do not always suppress immunity in the same way as chemotherapy. However, infection risk can increase because of:

• Combination chemotherapy
• Cellular-therapy conditioning treatment
• Low blood counts
• Loss of normal antibody-producing cells after selected CAR T therapies
• High-dose corticosteroids
• Other immune-suppressing medicines used to treat toxicity
• Central lines, hospitalization, or previous treatments

Fever, chills, cough, urinary symptoms, worsening diarrhea, line redness, or other possible infection should be reported according to the care plan.

Vaccinations

Ask the oncology or cellular-therapy team before receiving vaccines. Timing matters, and live vaccines may be unsafe during significant immune suppression. After cellular therapy, a structured revaccination plan may be required.

Family vaccination questions should also be discussed with the care team when the patient is severely immune-suppressed or has recently received cellular therapy.

Pregnancy

Some immunotherapies may harm a developing pregnancy or interfere with the immune tolerance required during pregnancy. Tell the oncology team immediately if you are pregnant, could be pregnant, or become pregnant during treatment.

Contraception

Patients who could become pregnant or cause a pregnancy should ask which contraception methods are recommended and how long pregnancy should be avoided during and after treatment. The timeframe differs by product.

Fertility

Immunotherapy’s direct fertility effects are not fully known for every treatment. Fertility may also be affected by chemotherapy, radiation, surgery, hormone changes, or conditioning therapy given with cellular treatment.

Patients interested in future biological parenthood should ask about sperm banking, egg or embryo freezing, ovarian-tissue preservation, and other options before treatment.

Breastfeeding

Many immunotherapy products may pass into breast milk or pose unknown risk to an infant. Ask whether breastfeeding must stop and for how long.

Sexual Health

Fatigue, hormonal changes, pain, anxiety, body-image concerns, and other cancer treatments can affect sexual health. Ask about endocrine care, fertility support, counseling, pelvic-floor therapy, or sexual-medicine services when needed.

Immunotherapy and Chemotherapy

Chemotherapy may release tumor antigens, reduce immune-suppressing cells, or directly control cancer while immunotherapy strengthens immune attack. The combination can also increase fatigue, infection risk, blood-count changes, nausea, and other toxicities.

Immunotherapy and Radiation

Radiation may release tumor antigens and alter the tumor environment. Combined treatment is used in selected cancers and studied widely. Lung, bowel, skin, liver, and other inflammatory effects can overlap.

Immunotherapy and Surgery

Immunotherapy may be given before surgery to produce a tumor response or after surgery to reduce recurrence risk. Timing must account for healing, immune effects, and other treatment.

Immunotherapy and Targeted Therapy

Targeted therapy may alter cancer signaling or the tumor environment in ways that complement immunotherapy. Combination treatment can also increase liver, skin, bowel, blood-pressure, and other effects.

Two Immunotherapies Together

Blocking more than one checkpoint or combining different immune approaches can strengthen antitumor activity but may substantially increase immune-related toxicity.

Some immunotherapy complications resolve completely. Others may persist or require long-term treatment.

Possible long-term issues include:

• Permanent thyroid, adrenal, pituitary, or pancreatic hormone deficiency
• Chronic joint, muscle, skin, bowel, lung, kidney, or nerve symptoms
• Persistent fatigue
• Long-term immune suppression after treatment of severe toxicity
• Recurrent infection or low antibody levels after selected cell therapies
• Delayed neurologic effects after certain cellular treatments
• Secondary malignancy monitoring after genetically modified cell therapy

Patients should request a treatment summary that includes:

• The exact immunotherapy name
• Treatment dates and number of doses
• Cellular-therapy product and target, when applicable
• Immune-related side effects
• Medicines used to manage toxicity
• Long-term laboratory or specialist follow-up
• Vaccination or infection-prevention plan
• Symptoms that remain important after treatment

Keep the treatment summary permanently. Future clinicians may need it when evaluating new endocrine, cardiac, pulmonary, neurologic, rheumatologic, or gastrointestinal symptoms.

Nutrition

Nutrition supports strength, immune recovery, healing, and treatment tolerance. Tell the team about reduced appetite, weight loss, diarrhea, vomiting, mouth problems, swallowing difficulty, or difficulty obtaining food.

Hydration

Diarrhea, vomiting, fever, adrenal problems, kidney inflammation, and poor intake can cause dehydration. Fluid recommendations should be individualized for patients with heart, kidney, or liver conditions.

Physical Activity

Safe movement may support strength, fatigue management, mood, sleep, and function. Activity should be adjusted for weakness, dizziness, neurologic symptoms, heart or lung inflammation, anemia, bone disease, fall risk, or recovery from cellular therapy.

Supplements and Special Diets

Do not begin high-dose vitamins, herbs, probiotics, fasting programs, or restrictive anticancer diets without oncology review. Supplements can interact with medicines, worsen liver injury, cause infection in vulnerable patients, or delay evaluation of immune toxicity.

Supportive care may help with anxiety, fatigue, sleep, pain, mobility, appetite, and emotional stress while evidence-based cancer treatment continues.

Depending on medical approval, services may include:

• Oncology nutrition
• Physical and occupational therapy
• Supervised exercise
• Mindfulness and relaxation practices
• Psychological counseling
• Support groups
• Spiritual care based on patient preference
• Massage adapted for oncology patients
• Acupuncture for selected symptoms
• Palliative care for symptom control and quality of life

Complementary care should not replace medically indicated immunotherapy or the urgent evaluation of possible immune toxicity.

National Center for Complementary and Integrative Health: Cancer and Complementary Approaches

Some patients continue working or attending school during routine checkpoint-inhibitor treatment. Others need reduced hours, remote work, medical leave, disability accommodations, or help with transportation.

Planning should consider:

• Fatigue
• Frequent laboratory and clinic visits
• Diarrhea or other unpredictable symptoms
• Infection risk
• Need for urgent access to the oncology team
• Driving restrictions after cellular therapy
• Distance from a specialized treatment center
• Potential hospitalization

Travel

Discuss travel before booking. Ask whether the destination has appropriate emergency care, whether laboratory monitoring is due, and whether a treatment alert card or medical summary should be carried.

Emergency Identification

Carry the treatment name, cancer center, oncology contact number, and last-dose date. Cellular-therapy patients should carry the identification card supplied by the treatment center.

Bring a written list, take notes, and consider bringing a trusted support person. Useful questions include:

1. What is the exact name and subtype of my cancer?
2. What is the stage and treatment goal?
3. What is the full generic name of the immunotherapy?
4. Which type of immunotherapy is it?
5. How does it work against my cancer?
6. How likely is it to help in my situation?
7. Which evidence or guideline supports this recommendation?
8. Do I need PD-L1, MSI, mismatch-repair, tumor-mutational-burden, antigen, HLA, or other biomarker testing?
9. What did my biomarker results show?
10. What alternatives are available?
11. What may happen without immunotherapy?
12. Will it be given alone or with chemotherapy, radiation, surgery, targeted therapy, or another immunotherapy?
13. How is the treatment given?
14. How often will I receive it?
15. How long is treatment expected to continue?
16. What would cause a treatment delay or permanent stop?
17. What side effects are most likely?
18. Which immune-related effects could be life-threatening?
19. Can side effects occur after treatment ends?
20. What symptoms require an immediate call?
21. Whom should I contact at night or on weekends?
22. Which emergency department should evaluate me?
23. Should I carry an immunotherapy alert card?
24. What blood tests and scans are required?
25. How will you determine whether treatment is working?
26. When will response imaging be performed?
27. Could an early scan show pseudoprogression?
28. How will suspected pseudoprogression be distinguished from true progression?
29. How are immune-related side effects treated?
30. Could I need corticosteroids or another immune-suppressing medicine?
31. Could a side effect require permanent hormone replacement?
32. Does my autoimmune disease affect treatment safety?
33. Does my transplant history affect the recommendation?
34. Which medicines, vaccines, vitamins, or supplements should I avoid?
35. Could treatment affect fertility or pregnancy?
36. What contraception is recommended, and for how long?
37. Is breastfeeding safe?
38. Can I work, exercise, drive, or travel?
39. Could a clinical trial be appropriate?
40. Can I meet with an oncology pharmacist, dietitian, rehabilitation specialist, fertility specialist, counselor, social worker, or financial navigator?
41. Will I receive a written treatment and survivorship summary?

Myth: Immunotherapy works for every cancer.

Fact: Immunotherapy benefits selected cancers and patients. Some tumors do not respond, and eligibility may depend on stage, target expression, biomarkers, or prior treatment.

Myth: Immunotherapy simply boosts the entire immune system.

Fact: Modern immunotherapies target specific checkpoints, antigens, receptors, cells, or immune pathways.

Myth: Immunotherapy has no serious side effects because it is natural.

Fact: Immune activation can cause serious or life-threatening inflammation of healthy organs.

Myth: Severe side effects prove that immunotherapy is working.

Fact: Toxicity does not guarantee treatment response.

Myth: Having no side effects means treatment has failed.

Fact: Effectiveness is measured through examinations, imaging, laboratory testing, pathology, and cancer control—not side-effect intensity.

Myth: Side effects can occur only while the drug is being infused.

Fact: Immune-related effects may begin between doses or after treatment has stopped.

Myth: Diarrhea during immunotherapy is always a minor stomach problem.

Fact: Diarrhea can be caused by immune inflammation of the colon and should be reported promptly.

Myth: Corticosteroids always cancel the benefit of immunotherapy.

Fact: Corticosteroids are an established treatment for immune-related toxicity. When medically indicated, controlling organ inflammation is the priority.

Myth: CAR T-cell therapy is a routine medication infusion.

Fact: CAR T therapy is a complex cellular treatment involving collection, manufacturing, conditioning, infusion, close monitoring, and long-term follow-up.

Myth: Supplements can reproduce cancer immunotherapy.

Fact: No vitamin, herb, detox program, or special diet substitutes for evidence-based checkpoint, antibody, vaccine, or cellular therapy.

Current immunotherapy research includes:

• New immune checkpoint targets
• Combinations of checkpoint inhibitors
• Immunotherapy with chemotherapy, targeted therapy, or radiation
• Personalized neoantigen vaccines
• Improved cancer treatment vaccines
• Next-generation bispecific and multispecific antibodies
• CAR T-cell therapy for solid tumors
• Off-the-shelf donor-derived cellular therapies
• CAR natural-killer-cell therapy
• Improved TIL and TCR therapies
• Ways to overcome immune resistance and T-cell exhaustion
• Biomarkers that better predict response and toxicity
• Microbiome research
• Methods to prevent or treat CRS, ICANS, and organ inflammation
• Strategies to preserve long-term immune function

Questions to ask about a trial include:

• What is the study designed to learn?
• Is the treatment experimental or already approved for another setting?
• What biomarker or target is required?
• How does the trial differ from standard care?
• Is the study randomized?
• What are the known and uncertain risks?
• What extra biopsies, travel, costs, or hospital stays are required?
• What treatment is available if I do not participate?

National Cancer Institute: Clinical Trials Using Immunotherapy

A second opinion may confirm eligibility, clarify biomarker interpretation, identify an alternative treatment sequence, or provide access to specialized cellular therapy or a clinical trial.

A second opinion may be especially valuable when:

• The cancer is rare.
• Biomarker results are unclear or conflicting.
• Several immunotherapy combinations are possible.
• The patient has autoimmune disease or an organ transplant.
• A CAR T, TIL, TCR, or other cellular therapy is being considered.
• The cancer progressed after prior immunotherapy.
• A severe immune-related reaction complicates the treatment decision.
• A clinical trial may provide an important option.

National Cancer Institute: Find an NCI-Designated Cancer Center

Immunotherapy costs vary according to the medicine or cellular product, treatment schedule, facility, insurance coverage, laboratory tests, imaging, toxicity management, and travel needs.

Potential expenses include:

• Drug or cellular-product charges
• Infusion-center or hospital fees
• Cell collection and manufacturing
• Conditioning chemotherapy
• Laboratory and imaging tests
• Hospitalization or intensive care
• Specialist consultations
• Medicines used to treat immune toxicity
• Hormone-replacement medicines
• Travel, lodging, parking, meals, or child care
• Loss of income or medical leave
• Long-term cellular-therapy follow-up

Before treatment, ask:

• Is prior authorization required?
• Are the oncologist, facility, laboratory, pharmacy, and specialists in network?
• Does coverage require a particular treatment center?
• Are biomarker tests covered?
• Which cellular-therapy costs are included in the authorization?
• Are travel or lodging benefits available?
• Is manufacturer or foundation assistance available?
• Can a financial navigator estimate total out-of-pocket expenses?

National Cancer Institute: Tracking and Managing Cancer-Care Costs

• □ I know the goal of immunotherapy.
• □ I know the full generic name of the treatment.
• □ I understand which type of immunotherapy it is.
• □ I understand my biomarker or target-testing results.
• □ I know the route, schedule, and expected treatment duration.
• □ I reported all autoimmune and inflammatory conditions.
• □ I reported every organ and stem-cell transplant.
• □ I provided a complete medicine and supplement list.
• □ Pregnancy, contraception, fertility, and breastfeeding were discussed.
• □ I understand the most likely side effects.
• □ I understand that side effects can occur after treatment ends.
• □ I know which symptoms require immediate contact.
• □ I have daytime and after-hours oncology numbers.
• □ I know which emergency department should evaluate me.
• □ I carry the treatment name and oncology contact information.
• □ I know the fever-reporting threshold.
• □ I understand that diarrhea, cough, rash, fatigue, and headache may require urgent evaluation.
• □ I know how frequently blood tests and scans are required.
• □ I understand work, driving, and travel restrictions.
• □ I will request a treatment and survivorship summary.

• National Cancer Institute — Immunotherapy to Treat Cancer
• National Cancer Institute — Immune Checkpoint Inhibitors
• National Cancer Institute — Monoclonal Antibodies
• National Cancer Institute — T-Cell Transfer Therapy
• National Cancer Institute — CAR T Cells
• National Cancer Institute — Cancer Treatment Vaccines
• National Cancer Institute — Immune-System Modulators
• National Cancer Institute — Side Effects of Immunotherapy
• National Cancer Institute — Immunotherapy and Organ Inflammation
• National Cancer Institute — Biomarker Testing for Cancer Treatment
• National Cancer Institute — A-to-Z List of Cancer Drugs
• National Cancer Institute — Cancer Types and Treatment Summaries
• American Cancer Society — Immunotherapy
• Cancer Research UK — Immunotherapy
• Canadian Cancer Society — Immunotherapy
• MedlinePlus — Cancer Immunotherapy
• U.S. Food and Drug Administration — CAR T-Cell Secondary Malignancy Warning
• National Center for Complementary and Integrative Health — Cancer and Complementary Approaches
• National Cancer Institute — Find an NCI-Designated Cancer Center
• National Cancer Institute — Immunotherapy Clinical Trials

Immunotherapy is not one drug or one treatment experience. It includes checkpoint inhibitors, antibodies, cancer treatment vaccines, immune modulators, and sophisticated cellular therapies designed for different cancers and immune targets.

For selected patients, immunotherapy can produce major and sometimes long-lasting cancer responses. For others, it may reduce recurrence risk, strengthen another treatment, control advanced cancer, or offer an option after previous therapies have stopped working.

Immunotherapy can also produce distinctive complications when activated immune cells inflame healthy organs. Safe care depends on biomarker-guided selection, careful baseline assessment, regular laboratory monitoring, early symptom reporting, rapid treatment of immune toxicity, and long-term follow-up when required.

Patients and families deserve a clear explanation of the treatment goal, expected benefit, alternatives, immune target, schedule, possible short- and long-term effects, emergency plan, costs, and how the oncology team will determine whether treatment is working.